- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00354913
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Evaluate the activity of imatinib mesylate and hydroxyurea, as measured by 6-month progression-free survival, in patients with recurrent or progressive meningioma.
Secondary
- Evaluate the progression-free survival (PFS)
- Overall survival (OS),
- Objective response rate among patients treated with this regimen.
OUTLINE: This is an open-label study.
Patients receive oral imatinib mesylate once or twice daily and oral hydroxyurea twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 21 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Histologically confirmed meningioma
- Recurrent or progressive disease after prior surgical resection
- Measurable disease by contrast-enhanced MRI
- Multifocal disease allowed
No evidence of intratumor hemorrhage on pretreatment diagnostic imaging
- Stable postoperative grade 1 hemorrhage allowed
- No peripheral edema or central or systemic fluid collections ≥ grade 2 (e.g., pericardial effusion, pulmonary effusion, ascites)
PATIENT CHARACTERISTICS:
- Karnofsky performance status 70-100%
- Absolute neutrophil count > 1,500/mm³
- Hemoglobin > 9 g/dL
- Platelet count > 100,000/mm³
- Potassium normal*
- Calcium normal*
- Magnesium normal*
- Phosphorus normal*
- alanine aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN)
- Bilirubin < 1.5 times ULN
- Creatinine < 1.5 times ULN OR creatinine clearance > 50 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No excessive risk of bleeding, as defined by stroke within the past 6 months
- No active systemic bleeding (i.e., gastrointestinal bleeding or gross hematuria)
- No history of central nervous system (CNS) or intraocular bleeding or septic endocarditis
No concurrent severe and/or uncontrolled medical disease, including any of the following:
- Uncontrolled diabetes
- Congestive cardiac failure
- Myocardial infarction within the past 6 months
- Poorly controlled hypertension
- History of labile hypertension
- History of poor compliance with antihypertensive regimen
- Chronic renal disease
- Active uncontrolled infection requiring intravenous antibiotics
- No acute or chronic liver disease (i.e., hepatitis, cirrhosis)
- No HIV positivity
No impairment of gastrointestinal function or disease that may significantly alter the absorption of imatinib mesylate, including any of the following:
- Ulcerative disease
- Uncontrolled nausea
- Vomiting
- Diarrhea
- Malabsorption syndrome
- Bowel obstruction
- Inability to swallow tablets
- No other malignancy within the past 5 years except basal cell skin cancer or cervical carcinoma in situ NOTE: *Unless correctable with supplements
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior therapy
- More than 1 week since prior tumor biopsy
- More than 2 weeks since prior surgical resection
- Prior hydroxyurea allowed provided patient has not had progressive disease or toxicity > grade 3
- No prior imatinib mesylate or other platelet-derived growth factor-directed therapy
At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)*
- Chemotherapeutic agents such as etoposide that are normally given at shorter intervals allowed even if < 4 weeks from last prior dose of chemotherapy
- At least 4 weeks since prior radiotherapy*
- At least 1 week since prior biological, immunotherapeutic, or cytostatic drugs
- At least 2 weeks since prior investigational drugs
- No concurrent warfarin NOTE: *Unless there is unequivocal evidence of tumor progression
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imatinib mesylate+hydroxyurea
All patients receive imatinib mesylate and hydroxyurea orally on a daily, continuous basis.
Dosing of imatinib mesylate is adjusted for patients who are also receiving p450-inducing anti-epileptic drugs.
|
Hydroxyurea is administered orally twice a day.
The dose will be set at 500 mg twice a day for all patients.
If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited.
It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
Other Names:
Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day. Dose for Imatinib: Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day. If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival at 6 Months
Time Frame: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months. For each participant, PFS was assessed at 6 months after treatment initiation.
|
Percentage of participants surviving six months from the start of study treatment without progression of disease.
PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or death due to any cause.
|
From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months. For each participant, PFS was assessed at 6 months after treatment initiation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression-free Survival (PFS)
Time Frame: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months.
|
Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause.
Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date.
Median PFS was estimated using a Kaplan-Meier curve.
|
From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months.
|
Median Overall Survival (OS)
Time Frame: From the date of study treatment initiation to the date of death from any cause, assessed up to 69 months.
|
Time in months from the start of study treatment to date of death due to any cause.
Patients alive at last follow-up are censored as of that follow-up date.
Median OS was estimated using a Kaplan-Meier curve.
|
From the date of study treatment initiation to the date of death from any cause, assessed up to 69 months.
|
Objective Response Rate
Time Frame: 69 Months
|
Percentage of participants with an objective response (complete response or partial response).
Per modified Macdonald criteria and assessed by MRI, complete response (CR) was the disappearance of all target lesions and partial response (PR) was a ≥50% decrease in the sum of the longest diameter of target lesions.
Objective response = CR+PR.
|
69 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David A. Reardon, MD, Duke Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms, Vascular Tissue
- Meningeal Neoplasms
- Glioblastoma
- Gliosarcoma
- Meningioma
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Antisickling Agents
- Imatinib Mesylate
- Hydroxyurea
Other Study ID Numbers
- Pro00006768
- DUMC-7082-05-4R0
- NOVARTIS-DUMC-7082-05-4R0
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on hydroxyurea
-
Shiraz University of Medical SciencesCompletedCombination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermediaβ-Thalassemia IntermediaIran, Islamic Republic of
-
Vanderbilt University Medical CenterAminu Kano Teaching Hospital; Murtala Muhammed Specialist HospitalCompletedStroke | Sickle Cell Disease | Sickle Cell AnemiaNigeria
-
Ain Shams UniversityUnknownThalassemia IntermediaEgypt
-
Vanderbilt University Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Aminu Kano... and other collaboratorsCompletedStroke | Sickle Cell DiseaseNigeria
-
ItalfarmacoCompletedPolycythemia VeraItaly
-
St. Jude Children's Research HospitalTerminatedSickle Cell Disease | ThalassemiaUnited States
-
UNICANCERCompletedBrain and Central Nervous System TumorsFrance
-
St. Jude Children's Research HospitalCompleted
-
St. Jude Children's Research HospitalCompletedAnemia, Sickle CellUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Anemia, Sickle Cell | Hemoglobinopathies